Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis

Tumor Biology

Volumn 36, Issue 10, 2015, Pages 7623-7630

  Zhong, Chen ^a   Wu, Jin Dao ^a   Fang, Ming Ming ^b   Pu, Li Yong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Cancer stem cells; CD133; Clinicopathological features; Hepatocellular carcinoma; Meta analysis; Prognosis

Indexed keywords

CD133 ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; TUMOR MARKER;

ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; HUMAN; LIVER CELL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; THROMBOSIS; TUMOR INVASION; CANCER STEM CELL; GENETICS; LIVER TUMOR; META ANALYSIS; PATHOLOGY; PROGNOSIS;

ANTIGENS, CD; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; GLYCOPROTEINS; HUMANS; LIVER NEOPLASMS; NEOPLASTIC STEM CELLS; PEPTIDES; PROGNOSIS;

EID: 84944276652     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3487-y     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Ma YC, Yang JY, Yan LN. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis. Eur J Gastroenterol Hepatol. 2013;25:1007–16.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.
4. Ho CM, Wu CY, Lee PH, Lai HS, Ho MC, Wu YM, et al. Analysis of the risk factors of untransplantable recurrence after primary curative resection for patients with hepatocellular carcinoma. Ann Surg Oncol. 2013;20:2526–33.
5. Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, et al. Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? Ann Surg. 2002;236:602–11.
6. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10–24.
7. Ding X, Yang LY, Huang GW, Yang JQ, Liu HL, Wang W, et al. Role of AFP mRNA expression in peripheral blood as a predictor for postsurgical recurrence of hepatocellular carcinoma: a systematic review and meta-analysis. World J Gastroenterol. 2005;11:2656–61.
8. Chun JM, Kwon HJ, Sohn J, Kim SG, Park JY, Bae HI, et al. Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma. J Surg Oncol. 2011;103:148–51.
9. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359:1995–2004.
10. Hixson DC, Brown J, McBride AC, Affigne S. Differentiation status of rat ductal cells and ethionine-induced hepatic carcinomas defined with surface-reactive monoclonal antibodies. Exp Mol Pathol. 2000;68:152–69.
11. Libbrecht L, Roskams T. Hepatic progenitor cells in human liver diseases. Semin Cell Dev Biol. 2002;13:389–96.
12. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.
13. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol. 2007;18:460–6.
14. Wang K, Liu L, Zhang T, Zhu YL, Qiu F, Wu XG, et al. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer. Int J Nanomedicine. 2011;6:3207–18.
15. Wang W, Chen Y, Deng J, Zhou J, Zhou Y, Wang S, et al. The prognostic value of CD133 expression in non-small cell lung cancer: a meta-analysis. Tumor Biol. 2014;35:9769–75.
16. Wang K, Xu J, Zhang J, Huang J. Prognostic role of CD133 expression in colorectal cancer: a meta-analysis. BMC Cancer. 2012;12:573.
17. Chen S, Song X, Chen Z, Li X, Li M, Liu H, et al. CD133 expression and the prognosis of colorectal cancer: systematic review and meta-analysis. PLoS One. 2013;8, e56380. doi:10.1371/journal.pone.0056380.
18. Wen L, Chen XZ, Yang K, Chen ZX, Zhang B, Chen JP, et al. Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review. PLoS One. 2013;8, e59154. doi:10.1371/journal.pone.0059154.
19. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract. 2008;62:1212–8.
20. Tsuchiya A, Kamimura H, Takamura M, Yamagiwa S, Matsuda Y, Sato Y, et al. Clinicopathological analysis of CD133 and NCAM human hepatic stem/progenitor cells in damaged livers and hepatocellular carcinomas. Hepatol Res. 2009;39:1080–90.
21. Yeh CT, Kuo CJ, Lai MW, Chen TC, Lin CY, Yeh TS, et al. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer. 2009;9:324.
22. Zhang H, Gao ZH, Xu TY, Zhu JF, Zhang Y. Expression of CD133 in hepatocellular carcinoma and its clinical significance. Cancer Res Clin. 2009;21:440–3.
23. Lingala S, Cui YY, Chen X, Ruebner BH, Qian XF, Zern MA, et al. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol. 2010;89:27–35.
24. Sasaki A, Kamiyama T, Yokoo H, Nakanishi K, Kubota K, Haga H, et al. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Rep. 2010;24:537–46.
25. Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010;59:953–62.
26. Guo XD, Wang HB, Qu F, Liu LM, Zhang JL, Li XX, et al. Expression of CD133 in hepatocellular carcinoma and its relationship with clinical pathological features. Clin J Lab Diagn. 2011;15:78–80.
27. Wu XH, Wang SX, Cui DP, Li JK, Yang BM. Expression and significance of CD133 and CD90 in hepatocellular carcinoma. Clin J Hepatol. 2011;19:376–7.
28. Zen C, Zen Y, Mitry RR, Corbeil D, Karbanová J, O’Grady J, et al. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl. 2011;17:943–54.
29. Pan QX, Su ZJ, Wang CR, Zhuang JN. Expression of tumor stem cell markers EpCAM and CD133 in human primary hepatocellular carcinoma and their value in prognostic prediction. Tumori. 2012;32:628–33.
30. Zeng XC, Zhang D, Fu BS, Chen W, Chen GZ, Li H, et al. Expression of CD133 as a tumor stem cell surface marker in hepatocellular and its significance in the prognosis of liver transplantation patients. Chin J Hepat Surg (Electronic Edition). 2012;1:51–6.
31. Liu LL, Li W, Li YJ. Expression of CD133 and CD90 in hepatocellular carcinoma tissue and their clinical significance. Acta Academiae Medicinae Qindao Universitatis. 2013;49:393–6.
32. Tian J, Gong XM. Expression and their relationship to clinicopathological significance of CD133 and maspin in hepatocellular carcinoma. Chinese Journal of Histochemistry and Cytochemistry. 2013;22:528–32.
33. Wu LM, Cheng CT, Chen XX, Wang JH, Liu HY, Tian L. Prognostic significance of expression of CD133, VEGF and CD34 in hepatocellular carcinoma. Clin J Cancer Prev Treat. 2013;20:998–1002.
34. Chan AW, Tong JH, Chan SL, Lai PB, To KF. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology. 2014;64:935–50.
35. Chen K, Li ZH, Jiang P, Zhang X, Zhang YJ, Jiang Y, et al. CD44, CD133 and TF correlate with formation of portal vein tumor thrombus and poor prognosis in patients with hepatocellular carcinoma. J Third Mil Med Univ. 2014;36:1068–73.
36. Guo Z, Li LQ, Jiang JH, Ou C, Zeng LX, Xiang BD. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma. World J Gastroenterol. 2014;20:2098–106.
37. Ye F, Jing YY, Guo SW, Yu GF, Fan QM, Qu FF, et al. Proliferative ductular reactions correlate with hepatic progenitor cell and predict recurrence in HCC patients after curative resection. Cell Biosci. 2014;4:50.
38. Yilmaz G, Akyol G, Cakir A, Ilhan M. Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis. Pathol Res Pract. 2014;210:419–25.
39. Zhao MY. Immunohistochemical analysis of CD133 and CD90 expression in hepatocellular carcinoma and its clinicopathological significance. Med Lab Sci. 2014; 104–5.
40. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
41. Zhang L, Li H, Ge C, Li M, Zhao FY, Hou HL, et al. Inhibitory effects of transcription factor Ikaros no the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma. Oncotarget. 2014;5:10621–35.
42. Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, et al. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology. 2012;55:807–20.
43. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 2006;351:820–4.
44. Ji J, Wang XW. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol. 2012;39:461–72.
45. Armeanu-Ebinger S, Wenz J, Seitz G, Leuschner I, Handgretinger R, Mau-Holzmann UA, et al. Characterisation of the cell line HC-AFW1 derived from a pediatric hepatocellular carcinoma. PLoS One. 2012;7, e38223. doi:10.1371/journal.pone.0038223.
46. Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ, et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res. 2008;6:1146–53.
47. Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer. 2010;126:2067–78.
48. Zheng YW, Tsuchida T, Shimao T, Li B, Takebe T, Zhang RR, et al. The CD133+ CD44+ precancerous subpopulation of oval cells is a therapeutic target for hepatocellular carcinoma. Stem Cells Dev. 2014;23:2237–49.